LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 91

Search options

  1. Article: Raising the Bar in the Management of IBS-C.

    Sayuk, Gregory S

    Gastroenterology & hepatology

    2024  Volume 19, Issue 10, Page(s) 613–620

    Language English
    Publishing date 2024-02-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Editorial: buspirone for gastroparesis-an intriguing option for a challenging condition.

    Sayuk, Gregory S

    Alimentary pharmacology & therapeutics

    2023  Volume 57, Issue 11, Page(s) 1347–1348

    MeSH term(s) Humans ; Buspirone/therapeutic use ; Gastroparesis/drug therapy
    Chemical Substances Buspirone (TK65WKS8HL)
    Language English
    Publishing date 2023-05-09
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.17511
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Digital Rectal Examination: Appropriate Techniques for the Evaluation of Constipation and Fecal Incontinence.

    Sayuk, Gregory S

    Gastroenterology clinics of North America

    2022  Volume 51, Issue 1, Page(s) 25–37

    Abstract: Disorders of defecation, including constipation and fecal incontinence, are very common. The digital rectal examination (DRE) is a key component in the early evaluation of patients with these complaints. Confident performance of a DRE requires dedicated ... ...

    Abstract Disorders of defecation, including constipation and fecal incontinence, are very common. The digital rectal examination (DRE) is a key component in the early evaluation of patients with these complaints. Confident performance of a DRE requires dedicated training for the clinician and hands-on experience with the technique. DRE can yield a diagnostic accuracy comparable to specialized physiologic tests, including anorectal manometry. This review will describe in detail the steps required to perform a thorough DRE evaluation, as well as the proper interpretation of observations. Thereafter, the current evidence-based findings supporting the value of DRE in defecatory disorders will be summarized.
    MeSH term(s) Anal Canal ; Constipation/diagnosis ; Constipation/etiology ; Fecal Incontinence/diagnosis ; Humans ; Manometry/methods ; Rectum
    Language English
    Publishing date 2022-01-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92114-2
    ISSN 1558-1942 ; 0889-8553
    ISSN (online) 1558-1942
    ISSN 0889-8553
    DOI 10.1016/j.gtc.2021.10.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome.

    Sayuk, Gregory S

    Gastroenterology clinics of North America

    2021  Volume 50, Issue 3, Page(s) 611–637

    Abstract: Diarrhea-predominant irritable bowel syndrome is a common functional gastrointestinal disorder that manifests with abdominal pain and diarrheal bowel patterns, without structural explanation. Diarrhea-predominant irritable bowel syndrome is a ... ...

    Abstract Diarrhea-predominant irritable bowel syndrome is a common functional gastrointestinal disorder that manifests with abdominal pain and diarrheal bowel patterns, without structural explanation. Diarrhea-predominant irritable bowel syndrome is a heterogeneous condition resulting from diverse pathophysiologic processes. Treatment strategies with varied mechanisms of action are beneficial in its management. The clinician must become familiar with a multi-dimensional approach to irritable bowel syndrome. The 3 approved medications are central to disease management. Effective treatment uses off-label medications and emerging therapies and a growing number of over-the-counter and supplemental agents to optimize symptom improvement for the patient with diarrhea-predominant irritable bowel syndrome.
    MeSH term(s) Abdominal Pain ; Diarrhea/drug therapy ; Diarrhea/etiology ; Gastrointestinal Diseases ; Humans ; Irritable Bowel Syndrome/complications ; Irritable Bowel Syndrome/drug therapy ; Treatment Outcome
    Language English
    Publishing date 2021-06-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92114-2
    ISSN 1558-1942 ; 0889-8553
    ISSN (online) 1558-1942
    ISSN 0889-8553
    DOI 10.1016/j.gtc.2021.04.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Editorial: Functional dyspepsia in pregnancy-Distinct approaches to a special population.

    Geisman, Taylor / Sayuk, Gregory S

    Alimentary pharmacology & therapeutics

    2023  Volume 58, Issue 2, Page(s) 250–251

    MeSH term(s) Female ; Pregnancy ; Humans ; Dyspepsia ; Gastritis
    Language English
    Publishing date 2023-06-23
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.17553
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Insights on Disorders of Gut-Brain Interaction.

    Sayuk, Gregory S

    Gastroenterology & hepatology

    2020  Volume 17, Issue 12, Page(s) 606–608

    Language English
    Publishing date 2020-02-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Tegaserod: What's Old Is New Again.

    Sayuk, Gregory S / Tack, Jan

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

    2022  Volume 20, Issue 10, Page(s) 2175–2184.e19

    Abstract: Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are common gastrointestinal disorders imposing considerable impact on the quality of life and well-being of affected individuals. A paucity of evidence-based ... ...

    Abstract Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are common gastrointestinal disorders imposing considerable impact on the quality of life and well-being of affected individuals. A paucity of evidence-based treatment options exist for CIC and IBS-C sufferers. Tegaserod, a 5-HT<sub>4</sub> agonist, has a substantial body of preclinical and clinical study evidence to support its beneficial role in modulating sensorimotor function of the luminal gastrointestinal tract. Tegaserod was first approved for use by the U.S. Food and Drug Administration for the management of IBS-C and CIC in 2002 and 2004, respectively. Tegaserod enjoyed a successful uptake in the management of these disorders during its first several years of availability in the United States, but was later withdrawn from the market in 2007 over concerns related to adverse cardiovascular events. Since then, additional safety data has been generated, and following a resubmission and review by the Food and Drug Administration, in April 2019, tegaserod was once again approved for use in IBS-C under a more restricted labeling, confining use to women under 65 years of age without heart disease or additional cardiovascular risk factors. This review summarizes the regulatory journey of tegaserod and details the existing pharmacokinetic, physiologic, clinical, and safety data of tegaserod generated over the last 2 decades. The discussion also examines the future of tegaserod in the treatment of these constipation disorders, as well as its potential role in other related disorders of brain-gut interaction.
    MeSH term(s) Constipation/drug therapy ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Indoles ; Irritable Bowel Syndrome/drug therapy ; Quality of Life ; Serotonin/therapeutic use ; Serotonin Receptor Agonists/therapeutic use
    Chemical Substances Gastrointestinal Agents ; Indoles ; Serotonin Receptor Agonists ; Serotonin (333DO1RDJY) ; tegaserod (458VC51857)
    Language English
    Publishing date 2022-02-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2119789-1
    ISSN 1542-7714 ; 1542-3565
    ISSN (online) 1542-7714
    ISSN 1542-3565
    DOI 10.1016/j.cgh.2022.01.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Management of Constipation in Hospitalized Patients.

    Sayuk, Gregory S / Yu, Qi T / Shy, Corey

    Journal of clinical medicine

    2023  Volume 12, Issue 19

    Abstract: Constipation is frequently encountered in hospital settings and can have potentially serious consequences yet is often underrecognized and undertreated. Opioid-induced constipation is a common cause of constipation in hospitalized patients. Opioids ... ...

    Abstract Constipation is frequently encountered in hospital settings and can have potentially serious consequences yet is often underrecognized and undertreated. Opioid-induced constipation is a common cause of constipation in hospitalized patients. Opioids induce constipation through agonistic effects on enteric µ-opioid receptors. This review aims to provide insight on the identification and management of constipation in inpatient settings, with a particular focus on opioid-induced constipation. Constipation assessment should be routinely initiated at hospital admission and can be facilitated by thorough symptom assessments; relevant patient history, including recent medication use; physical examination; and patient assessment tools developed to evaluate the impact of constipation. Management of opioid-induced constipation should begin with ensuring adequate hydration and electrolyte balance and encouraging patient mobilization. Other treatments may include laxatives, enemas, intestinal secretagogues, peripherally acting µ-opioid receptor antagonists, and manual disimpaction. Surgical intervention may be required for some patients as a salvage therapy in severe, refractory cases.
    Language English
    Publishing date 2023-09-23
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12196148
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions.

    Tait, Christopher / Sayuk, Gregory S

    European journal of internal medicine

    2021  Volume 84, Page(s) 1–9

    Abstract: Functional gastrointestinal disorders (FGIDs), characterized by chronic abdominal complaints without a structural or biochemical cause, are common diseases that are frequently encountered by specialists in internal medicine. Collectively, irritable bowel ...

    Abstract Functional gastrointestinal disorders (FGIDs), characterized by chronic abdominal complaints without a structural or biochemical cause, are common diseases that are frequently encountered by specialists in internal medicine. Collectively, irritable bowel syndrome (IBS) and functional dyspepsia are estimated to affect up to 22% of the population, and are often associated with additional somatic and pain complaints, all without an obvious structural source [1,2]. An appreciation of the current understanding of the mechanistic basis for these disorders is key to developing treatment goals and optimization of patient management strategies. In recent years, the brain-gut axis increasingly has been recognized as a central factor in the experience of functional abdominal pain disorders, including the most recent Rome IV guidelines which identify FGIDs as disorders of gut-brain interaction [3]. The brain-gut axis (BGA), simply defined, is a complex network of bidirectional communication between the central and enteric nervous systems. This axis broadly includes all the systems involved with communication between the GI tract and central nervous system (CNS), with principle inputs into this network occurring between the CNS, enteric nervous system (ENS), and autonomic nervous systems (ANS), but also includes interfaces with numerous other factors, including endocrine hormones and immune effector cells as well as interactions with the gut microbiota. Perturbances to this system have been found to play a critical role in the development of visceral hypersensitivity, bowel dysregulation, and mood. This review will summarize the principle processes involved in the neurologic and biologic function of the brain-gut axis, our current understanding of its role in functional GI disorders, and potential targets for therapeutic intervention.
    MeSH term(s) Abdominal Pain ; Brain ; Enteric Nervous System ; Gastrointestinal Diseases/therapy ; Humans ; Irritable Bowel Syndrome/therapy
    Language English
    Publishing date 2021-01-07
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2020.12.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Editorial: felcisetrag-forward movement as a novel prokinetic for gastroparesis.

    Rogers, Benjamin D / Sayuk, Gregory S

    Alimentary pharmacology & therapeutics

    2021  Volume 53, Issue 10, Page(s) 1158–1159

    MeSH term(s) Gastric Emptying/drug effects ; Gastrointestinal Agents/pharmacology ; Gastrointestinal Agents/therapeutic use ; Gastroparesis/drug therapy ; Humans ; Receptors, Serotonin, 5-HT4/therapeutic use
    Chemical Substances Gastrointestinal Agents ; Receptors, Serotonin, 5-HT4 (158165-40-3)
    Language English
    Publishing date 2021-04-21
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.16334
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top